Business Context and Reporting Period
This Form 8-K filing by Travere Therapeutics, Inc. (TVTX) reports a significant executive leadership transition. The report date is September 21, 2026. The filing details the departure of Eric Dube, Ph.D., as President, Chief Executive Officer, and Board member, effective December 1, 2026, and the appointment of Bradley L. Campbell as his successor.
Key Financial Metrics and Compensation
This filing does not contain standard financial performance metrics such as revenue, profit, cash flow, or debt levels. The financial data provided relates exclusively to executive compensation and severance arrangements:
- Bradley L. Campbell (New CEO):
- Annual Base Salary: $1,000,000.
- Target Annual Bonus: 85% of base salary ($850,000).
- Initial Equity Awards: Non-qualified stock option (~$8.25M value) and time-based RSUs (~$8.25M value), vesting over four years.
- Future Performance Equity: RSUs (~$3.75M value) to be granted in early 2027.
- Expense Reimbursement: $500,000 cash payment (subject to clawback if employment ends early without Good Reason or for Cause).
- Eric Dube (Outgoing CEO):
- Continues to receive current base salary through the transition period ending February 15, 2027.
- Eligible for 2026 annual cash incentive bonus; not eligible for 2027 bonus.
- Existing equity awards continue to vest during the transition period.
- COBRA health insurance premiums covered for up to 18 months post-resignation.
Material Changes
The primary material change is the change in senior management and board composition effective December 1, 2026:
- Departure: Eric Dube, Ph.D., will step down as CEO and Board member. He will serve as Executive Advisor until February 15, 2027, and subsequently as a Consultant.
- Appointment: Bradley L. Campbell, formerly CEO of Amicus Therapeutics (acquired by BioMarin in April 2026), will assume the roles of President, CEO, and Board member.
Outlook, Risks, and Contingencies
Management Commentary and Transition: The transition is described as mutually agreed upon to facilitate a smooth handover. Dr. Dube will assist in transitioning duties during the period between December 1, 2026, and February 15, 2027.
Severance and Change in Control Provisions:
- Without Cause/Good Reason: Mr. Campbell is eligible for 1.5x (salary + target bonus) severance and accelerated equity vesting (18-month pro-rata).
- Change in Control: If termination occurs within 3 months prior to or 12 months following a Change in Control, Mr. Campbell is eligible for 2.0x (salary + target bonus) severance and full acceleration of all equity awards.
- Disability/Death: Specific severance packages include 18 months of salary (Disability) or pro-rata bonus (Death) with accelerated equity vesting.
Risks: The filing includes standard forward-looking statement disclaimers regarding the timing of the transition, the terms of employment, and the potential for actual outcomes to differ due to human capital risks and business needs.
Investor Verification Checklist
- Verify the exact effective date of the leadership change (December 1, 2026) and the duration of the transition period.
- Review the full text of the Transition and Separation Agreement (Exhibit 10.1) for specific conditions regarding Dr. Dube's equity forfeiture and consulting terms.
- Review the full text of the Employment Agreement (Exhibit 10.2) to understand the specific definitions of "Good Reason," "Cause," and "Change in Control" which trigger significant severance payouts.
- Confirm the clawback provisions for the $500,000 expense payment to Mr. Campbell if he resigns or is terminated for cause within the first 24 months.
- Monitor future filings for the grant of the performance-based RSUs to Mr. Campbell scheduled for early 2027.